Vor Biopharma Inc. (VOR)

NasdaqGS: VOR · 即時價格 · USD

22.34

-0.89 (-3.83%)

收盤價： Sep 10, 2026, 3:59 PM

22.19

-0.65%

盤後: 7:50 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-3.85% (1D)

買價	21
市值	1.32B
營收 (ttm)	n/a
淨利（ttm）	628M
	1.72
	173.81
	0.13
	-5.86
P/B (ttm)	-6.08
P/S (ttm)	0.00
財報日期	Nov 12, 2026

賣價	23.5
成交量	686,878
20 日平均成交量	1,157,662
開盤價	22.96
前收盤價	23.23
當日區間	22.09 - 23.09
52 週範圍	6.50 - 49.95
分析師	強<br>購買
目標價	40 (79.05%)
股利	n/a
除息日	n/a

關於 VOR

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, ...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Feb 5, 2021

員工 76

證券交易所 NasdaqGS

股票代號 VOR

網站 https://www.vorbio.com

完整的公司簡介

財務表現

Vor Biopharma 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -695.98M，較前期增加 495.29%。

財務報表

分析師預測

根據 8 位分析師的評等，VOR 的平均評等為「Strong Buy」。12 個月目標價為 40，較最新價格有 79.05% 的上漲空間。

股票預測

財報驚奇

Vor Biopharma 已於 Aug 11, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.8 低於預期 -0.10, 年增 99.68% 成長.

下次財報發布

Vor Biopharma Inc. 的下次財報預計於 Nov 12, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 月前 · Simply Wall St.

Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next

In late June 2026, Vor Biopharma Inc. was added to a broad suite of FTSE Russell indices, including the Russell 2000, 2500, 3000, Microcap, and related growth and value benchmarks. This sweeping inclu...

3 月前 · Motley Fool

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

3 月前 · Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

3 月前 · Simply Wall St.

We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

4 月前 · Zacks

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

第 1 頁，共 2 頁

Vor Biopharma Inc. (VOR)